Comparison Chart Fate Therapeutics, Inc.

Stocks

FATE

US31189P1021

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 23/10/2026 +03			5-day change	1st Jan Change
2.110 ^USD	+0.96%		+17.88%	+114.74%

10-12	Fate Therapeutics, Inc. Announces Appointment of Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, Effective October 12, 2026	CI
09-25	Fate Therapeutics Receives $15.0 Million California Institute For Regenerative Medicine CLIN2 Grant To Support Advancement Of RECLAIM-LN	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	FATE THERAPEUTICS, INC.	Bio Therapeutic Drugs	+0.96%	+17.88%	+114.74%	+38.82%	-96.42%	253M